Ubs Group Ag Provention Bio, Inc. Put Options Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Put Options

0 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
No transaction found.

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0
View Full List

About Provention Bio, Inc.

PRVB Quotes by TradingView
  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email